Luis Alejandro Barrera Avellaneda - La criptología de la enfermedad

4.Garrod AE. The Chemistry of the Species in Inborn Errors of Metbolism. 1923. p. 1–16.

5.Ezgu F. Inborn Errors of Metabolism. In: Advances in clinical chemistry [Internet]. 2016. p. 195–250. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26975974

6.Ferreira CR, Rahman S,Keller M, Zschocke J, ICIMD Advisory Group. Aninternational classification of inherited metabolic disorders (ICIMD). J Inherit Metab Dis. 2021;44:164–177. https://doi.org/10.100

7.Beadle GW. Genes and Chemical Reactions in Neurospora: The concepts of biochemical genetics began with Garrod’s “inborn errors” and have evolved gradually. Science [Internet]. 1959 Jun;129(3365):1715–9. Available from: http://www.sciencemag.org/cgi/doi/10.1126/science.129.3365.1715

8.Sankaranarayanan K. Ionizing radiation and genetic risks I. Epidemiological, population genetic, biochemical and molecular aspects of mendelian diseases. Mutat Res Genet Toxicol. 1991;258(1):3–49.

9.Elliott HR, Samuels DC, Eden JA, Relton CL, Chinnery PF. Pathogenic Mitochondrial DNA Mutations Are Common in the General Population. Am J Hum Genet [Internet]. 2008;83(2):254–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18674747

10.Tomatsu S, Montano AM, Nishioka T, Gutierrez MA, Pena OM, Tranda Firescu GG, et al. Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A). Hum Mutat. 2005;26(6):500–12.

11.Peneva L. Prader-Willi syndrome–rhGH-treatment. Pediatriya. 2010.

12.Kaplan F. Tay-Sachs disease carrier screening: a model for prevention of genetic disease. Genet Test. 1998;2(4):271–92.

13.Piran S, Amato D. Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment. J Inherit Metab Dis [Internet]. 2010 Jun;33(3):271–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20336376

14.MacQueen GM, Rosebush PI, Mazurek MF. Neuropsychiatric aspects of the adult variant of Tay-Sachs disease. J Neuropsychiatry Clin Neurosci. 1998;10(1):10–9.

15.Ficicioglu C, An Haack K. Failure to thrive: when to suspect inborn errors of metabolism. Pediatrics [Internet]. 2009;124(3):972–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19706585

16.El-Hattab AW, Sutton VR. Approach to Inborn Errors of Metabolism in Pediatrics. Pediatr Clin North Am. 2018.

17.Ahrens-Nicklas RC, Slap G, Ficicioglu C. Adolescent presentations of inborn errors of metabolism. Journal of Adolescent Health. 2015;56:477-82.

18.Garrod AE. A Contribution to the Study of Alkaptonuria. Med Chir Trans [Internet]. 1899;82:367–94. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2036698/

19.Garrod. The Incidence of Alkaptonuria: A study on Chemical Individuality. Lancet. 1902;II:1616–20.

20.Sewell AC, Haskins ME, Giger U. Inherited metabolic disease in companion animals: Searching for nature’s mistakes. Veterinary Journal. 2007.

21.Rijnberk A, De Vijlder JJ, Van Dijk JE, Jorna TJ, Tegelaers WH. Congenital defect in iodothyronine synthesis. Clinical aspects of iodine metabolism in goats with congenital goitre and hypothyroidism. Br Vet J. 1977.

22.Haskins M, Giger U, Patterson D. Animal models of lysosomal storage diseases: their development and clinical relevance. Fabry Dis Perspect from 5 years FOS. 2006.

23.Sewell AC, Haskins ME, Giger U. Inherited metabolic disease in companion animals: Searching for nature’s mistakes. Veterinary Journal. 2007.

24.Gurda BL, Bradbury AM, Vite CH. Canine and feline models of human genetic diseases and their contributions to advancing clinical therapies. Yale Journal of Biology and Medicine. 2017.

25.Bath GF, Wentzel D, van Tonder EM. Cretinism in Angora goats. J S Afr Vet Assoc. 1979.

26.Ramakrishna C, Prasad MC, Ramkumar, Sharma AK. Prevalence of goitre/hypothyroidism in goats in and around Bareilly (U.P.). Indian Vet Med J. 1991.

27.Stern JR, Ochoa S. Enzymatic synthesis of acetyl phosphate. J Biol Chem [Internet]. 1951. Available from: https://pdfs.semanticscholar.org/a9d0/0256dba1b01612c028437c03588784b364e5.pdf

28.Barnett JA. A history of research on yeasts 5: The fermentation pathway. Yeast. 2003;20(6):509–43.

29.Zhang XK, Elbin CS, Chuang W-L, Cooper SK, Marashio CA, Beauregard C, et al. Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry. Clin Chem. 2008;54(10):1725–8.

30.Baussan C, Moatti N, Odievre M, Lemonnier A. Liver glycogenosis caused by a defective phosphorylase system: hemolysate analysis. Pediatrics [Internet]. 1981 Jan;67(1):107–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6787554

31.National Human Genome Research Institute. All About The Human Genome Project (HGP)–National Human Genome Research Institute (NHGRI). NIH. 2015.

32.Koeppen AH. The hereditary ataxias [Internet]. Sixth Edit. Vol. 57, Journal of Neuropathology and Experimental Neurology. Elsevier; 1998. 531–543 p. Available from: http://dx.doi.org/10.1016/B978-0-12-383834-6.00125-7

33.Opal P, Zoghbi H. Chapter 118–The Hereditary Ataxias [Internet]. Sixth Edit. Vol. 7, Emery and Rimoin’s Principles and Practice of Medical Genetics (Sixth Edition). Elsevier; 2013. 1–32 p. Available from: http://www.sciencedirect.com/science/article/pii/B9780123838346001257

34.Narravula A, Garber KB, Askree SH, Hegde M, Hall PL. Variants of uncertain significance in newborn screening disorders: implications for large-scale genomic sequencing. Genet Med. 2017 Jan 1;19(1):77–82.

35.Al Hafid N, Christodoulou J. Phenylketonuria: a review of current and future treatments. Transl Pediatr [Internet]. 2015;4(4):304–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26835392%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4728993

36.Camp KM, Parisi MA, Acosta PB, Berry GT, Bilder DA, Blau N, et al. Phenylketonuria scientific review conference: State of the science and future research needs. Mol Genet Metab. 2014;112(2):87–122.

37.Brady RO. Enzyme replacement therapy: conception, chaos and culmination. Philos Trans R Soc B Biol Sci [Internet]. 2003 May;358(1433):915–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12803925

38.Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis. 2004;27(3):385–410.

39.Broomfield A, Fletcher J, Davison J, Finnegan N, Fenton M, Chikermane A, et al. Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy. J Inherit Metab Dis. 2016 Mar;39(2):261–71.

40.Rombach SM, Smid BE, Linthorst GE, Dijkgraaf MGW, Hollak CEM. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis. 2014 May;37(3):341–52.

41.Rodríguez A, Espejo ÁJ, Hernández A, Velásquez OL, Lizaraso LM, Cordoba HA, et al. Enzyme replacement therapy for Morquio A: an active recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in Escherichia coli BL21. J Ind Microbiol Biotechnol [Internet]. 2010 [cited 2018 Apr 15];37:1193–201.

42.Almeciga CJ, Rodríguez-López A, Sánchez J, Moreno J, Diaz D, Beltran LM, et al. Production of an active recombinant human N-acetylgalactosamine-6-sulfate sulfatase enzyme in Pichia pastoris. In: Lysosomal Disease Network congress world symposium [Internet]. 2013. p. S19. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1096719213004551

43.Von Figura, K y Hasilik, A. (1986). Lysosomal enzymes and their receptors. Annual Review of Biochemistry, vol. 55, 167-193. https://doi.org/10.1146/annurev.biochem.55.1.167.

44.Barrera LA, Galindo GC. Ethical aspects on rare diseases. Adv Exp Med Biol. 2010;686:493–511.

45.Hawking S. Life in the Universe [Internet]. Lecture. 1996 [cited 2020 Feb 13]. Available from: http://www.hawking.org.uk/life-in-the-universe.html